Literature DB >> 9151836

Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

E Tiganos1, X J Yao, J Friborg, N Daniel, E A Cohen.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) vpu gene encodes a 16-kDa class I integral membrane phosphoprotein with an N-terminal membrane-spanning region and a C-terminal cytoplasmic domain. In the cytoplasmic domain, two amphipathic alpha-helices joined by a flexible turn containing two phosphoacceptor sites have been predicted. Previous studies have shown that Vpu downregulates CD4 molecules by inducing their specific degradation in the endoplasmic reticulum. Phosphorylation of serine residues 52 and 56, present within the cytoplasmic domain of the Vpu protein, has been shown to be essential to this Vpu function. However, the contribution of these two phosphoacceptor sites in the mechanism of CD4 degradation remains undefined. Interestingly, a specific interaction between Vpu and CD4 was recently demonstrated in coimmunoprecipitation experiments. Binding of Vpu was shown to be necessary but not sufficient to mediate CD4 degradation, indicating that interaction between Vpu and CD4 represents an early step critical in triggering a process leading to CD4 degradation. To delineate the sequence(s) and/or structural determinant(s) involved in this Vpu-CD4 interaction and in the Vpu-mediated CD4 degradation, we performed a mutational analysis of the cytoplasmic domain of CD4 and Vpu. Coimmunoprecipitation experiments reveal that disruption of the putative alpha-helical structure in the membrane-proximal cytoplasmic domain of CD4 affects the binding to Vpu, suggesting that this structure may act as an interface for the CD4-Vpu interaction that mediates CD4 degradation. Vpu proteins containing mutations in either or both of the phosphoacceptor sites (Ser52 or/and Ser56) were inactive in regard to CD4 degradation yet retained the capacity to interact with the cytoplasmic domain of CD4. In an attempt to define the minimal region responsible for this interaction, we tested a panel of mutations which were designed to affect the integrity of the putative alpha-helices present in the cytoplasmic domain of Vpu. Our results indicate that although both C-terminal alpha-helices are required for degradation of CD4, only alpha-helix I, located in the membrane-proximal cytoplasmic region of Vpu, is involved in the interaction between Vpu and CD4. Taken together, these results demonstrate that alpha-helical structures in the HIV-1 Vpu and CD4 proteins are involved in binding and degradation of CD4 molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151836      PMCID: PMC191664     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export.

Authors:  X J Yao; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation.

Authors:  F Margottin; S Benichou; H Durand; V Richard; L X Liu; E Gomas; R Benarous
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein.

Authors:  F Maldarelli; M Y Chen; R L Willey; K Strebel
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  The effect of vpu on HIV-1-induced syncytia formation.

Authors:  X J Yao; S Garzon; F Boisvert; W A Haseltine; E A Cohen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-02

5.  Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins.

Authors:  J Garnier; D J Osguthorpe; B Robson
Journal:  J Mol Biol       Date:  1978-03-25       Impact factor: 5.469

6.  Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4.

Authors:  M E Lenburg; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum.

Authors:  M J Vincent; N U Raja; M A Jabbar
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Synthesis and characterization of the hydrophilic C-terminal domain of the human immunodeficiency virus type 1-encoded virus protein U (Vpu).

Authors:  P Henklein; U Schubert; O Kunert; S Klabunde; V Wray; K D Klöppel; M Kiess; T Portsmann; D Schomburg
Journal:  Pept Res       Date:  1993 Mar-Apr

9.  Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity.

Authors:  M Y Chen; F Maldarelli; M K Karczewski; R L Willey; K Strebel
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function.

Authors:  R J Geraghty; A T Panganiban
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  19 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

2.  Endocytic activity of HIV-1 Vpu: Phosphoserine-dependent interactions with clathrin adaptors.

Authors:  Charlotte A Stoneham; Rajendra Singh; Xiaofei Jia; Yong Xiong; John Guatelli
Journal:  Traffic       Date:  2017-06-27       Impact factor: 6.215

Review 3.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

4.  CXCR4 is down-regulated in cells infected with the CD4-independent X4 human immunodeficiency virus type 1 isolate m7NDK.

Authors:  S T Valente; C Chanel; J Dumonceaux; R Olivier; S Marullo; P Briand; U Hazan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.

Authors:  M Paul; S Mazumder; N Raja; M A Jabbar
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.

Authors:  M Sarah Hill; Autumn Ruiz; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

7.  Structural determination of virus protein U from HIV-1 by NMR in membrane environments.

Authors:  Hua Zhang; Eugene C Lin; Bibhuti B Das; Ye Tian; Stanley J Opella
Journal:  Biochim Biophys Acta       Date:  2015-09-08

8.  Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Authors:  Takeshi Yoshida; Yoshio Koyanagi; Klaus Strebel
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

10.  The T cell receptor triggering apparatus is composed of monovalent or monomeric proteins.

Authors:  John R James; James McColl; Marta I Oliveira; Paul D Dunne; Elizabeth Huang; Andreas Jansson; Patric Nilsson; David L Sleep; Carine M Gonçalves; Sara H Morgan; James H Felce; Robert Mahen; Ricardo A Fernandes; Alexandre M Carmo; David Klenerman; Simon J Davis
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.